Stockreport

SciSparc gets U.S. FDA nod to begin phase 2 trial of Tourette Syndrome candidate Sep. 23, 2024 2:18 PM ET By: Jonathan Block , SA News Editor [Seeking Alpha]

SciSparc Ltd.  (SPRC) 
PDF Other phase 2b studies will also be conducted in Germany and Israel. The double-blind, placebo-controlled phase 2b program's primary endpoint is tic severity change [Read more]